Indexat a

Llicència i ús

Citacions

Cited 17 times in

Cited 15 times in

Altmetrics

Grant support

This study was funded by the Barcelona Magic Line fundraising program to C.L. J.C.J.-C. and D.S.-I. are Miguel Servet investigators (Carlos III National Institute of Health, Spain).

Anàlisi d'autories institucional

Compartir

Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial

Publicat a:Nutrients. 12 (10): 3123-14 - 2020-10-01 12(10), DOI: 10.3390/nu12103123

Autors: Amat-Bou, Montse; Garcia-Ribera, Sonika; Climent, Eric; Piquer-Garcia, Irene; Corripio, Raquel; Sanchez-Infantes, David; Villalta, Laia; Elias, Maria; Jimenez-Chillaron, Josep C; Chenoll, Empar; Ramon, Daniel; Ibanez, Lourdes; Ramon-Krauel, Marta; Lerin, Carles

Afiliacions

Resum

Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1 ' s effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo-BPL1 (n = 19) or BPL1-placebo (n = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray absorptiometry. Secondary outcomes included lipid and glucose metabolism, hyperphagia, and mental health symptoms. Generalized linear modeling was applied to assess differences between treatments. While BPL1 did not modify total fat mass compared to placebo, BPL1 decreased abdominal adiposity in a subgroup of patients older than 4.5 years (n = 28). BPL1 improved fasting insulin concentration and insulin sensitivity. Furthermore, we observed modest improvements in some mental health symptoms. A follow-up trial with a longer treatment period is warranted to determine whether BPL1 supplementation can provide a long-term therapeutic approach for children with PWS (ClinicalTrials.gov NCT03548480).

Paraules clau